Cancer diagnostics market seen reaching $44.69B by 2030

The Business Research Company says the global cancer diagnostics market was valued at $25.5 billion in 2025 and is forecast to reach $44.69 billion by 2030, driven by higher healthcare spending, more cancer screening, and wider use of AI and next-generation sequencing. North America held the largest share in 2025, while Asia-Pacific ranked second.

Why it matters: - Cancer diagnostics sits at the center of earlier detection, treatment planning, and patient outcomes. - Faster growth in the market points to more demand for imaging, molecular tests, biomarker assays, and lab automation. - Rising spending on healthcare and oncology is helping expand access to advanced diagnostic tools.

What happened: - The Business Research Company released a cancer diagnostics market report on July 29, 2026. - The report values the market at $25.5 billion in 2025. - The market is expected to reach $28.58 billion in 2026, a 12.1% increase. - The report forecasts the market will grow to $44.69 billion by 2030, at an 11.8% CAGR. - North America held the largest market share in 2025. - Asia-Pacific ranked as the second-largest regional market. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East, and Africa. - A free sample and the full report are available at the company’s sample page and the full market report.

The details: - The report links historical growth to higher cancer prevalence, more oncology research funding, stronger hospital diagnostic infrastructure, greater use of imaging, and more laboratory automation. - Future growth is expected to come from demand for personalized cancer treatment, broader adoption of next-generation sequencing diagnostics, wider population screening, more AI-enabled oncology diagnostics, and innovation in multi-cancer detection. - The report highlights molecular diagnostics, companion diagnostics, biomarker-based tests, high-throughput platforms, and early screening as key future trends. - Cancer diagnostics includes imaging, biopsy analysis, molecular profiling, and biomarker assays used to detect cancer, stage disease, and characterize tumor biology. - Rising healthcare expenditure is described as a major driver because it supports advanced screening, better access to early detection, specialized laboratories, and new diagnostic equipment. - The UK Office for National Statistics reported a 5.6% nominal increase in total healthcare spending in 2023 in a May 2024 update. - Lung cancer incidence is also fueling demand for diagnostics. - ASCO estimated 238,340 lung cancer diagnoses in the United States in 2023, up from 236,000 in 2022.

Between the lines: - The market forecast suggests cancer diagnostics is shifting from a core clinical function to a technology-intensive growth area. - AI, sequencing, and multi-cancer detection point to a broader move toward earlier, more personalized, and more automated diagnosis. - Regional leadership in North America and the strong position of Asia-Pacific suggest both mature reimbursement markets and fast-expanding demand centers remain important.

What's next: - The report expects more investment in AI-enabled diagnostics and population-level screening programs. - Diagnostic vendors are likely to keep pushing biomarker, molecular, and high-throughput platforms as competition intensifies. - Market growth will likely track healthcare budgets, cancer incidence, and adoption of new testing technologies.